Literature DB >> 759613

Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.

A S Hollister, G R Breese, R A Mueller.   

Abstract

The potentiation of the stimulatory response to L-dihydroxyphenylalanine (L-dopa) in 6-hydroxydopamine-treated rats given a peripheral decarboxylase inhibitor occurred only after treatments that destroyed dopamine-containing fibers, Destruction of serotonin- or norepinephrine-containing fibers did not potentiate the action of L-dopa. Furthermore, other data indicated thatL-dopa-induced activity could not be attributed to release of serotonin or to the formation of norepinephrine. That the L-dopa must be converted to catecholamines was demonstrated by antagonism of the activity responses to L-dopa with inhibition of decarboxylases in brain. After destruction of serotonin-containing fibers with 5,7-dihydroxytryptamine, L-dopa-induced activity in 6-hydroxydopamine-treated rats was significantly reduced, as was the accumulation of dopamine formed from L-dopa. These latter data provide direct evidence that serotonergic fibers contribute to the accumulation of dopamine in brain after L-dopa administration to 6-hydroxydopamine-treated rats.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759613

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

2.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

Review 3.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

4.  6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.

Authors:  G R Breese; G E Duncan; T C Napier; S C Bondy; L C Iorio; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

5.  Enhanced muscimol-induced behavioral responses after 6-OHDA lesions: relevance to susceptibility for self-mutilation behavior in neonatally lesioned rats.

Authors:  G R Breese; K L Hulebak; T C Napier; A Baumeister; G Frye; R A Mueller
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.

Authors:  Tomas Björklund; Thomas Carlsson; Erik Ahlm Cederfjäll; Manolo Carta; Deniz Kirik
Journal:  Brain       Date:  2010-02-02       Impact factor: 13.501

7.  Targeted manipulation of serotonergic neurotransmission affects the escalation of aggression in adult male Drosophila melanogaster.

Authors:  Olga V Alekseyenko; Carol Lee; Edward A Kravitz
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

8.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

9.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18

10.  Striatal glutamate release in L-DOPA-induced dyskinetic animals.

Authors:  Nina Nevalainen; Martin Lundblad; Greg A Gerhardt; Ingrid Strömberg
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.